Quantification of fibroblast growth factor 23 and N-terminal pro-B-type natriuretic peptide to identify patients with atrial fibrillation using a high-throughput platform: A validation study

Winnie Chua(University of Birmingham), Larissa Fabritz(University of Birmingham), G Neculau(University Hospitals Birmingham NHS Foundation Trust), František Neháj(Sandwell & West Birmingham Hospitals NHS Trust), K Russell(Sandwell & West Birmingham Hospitals NHS Trust), Paulus Kirchhof(University of Birmingham), Charles J. Ferro(Queen Elizabeth Hospital Birmingham), Samantha Tull(University of Birmingham), A. Turner(Sandwell & West Birmingham Hospitals NHS Trust), Peter Kastner(Roche Pharma AG (Germany)), Muhammad Jawad‐Ul‐Qamar(University of Birmingham), Victor Roth Cardoso(University of Birmingham), Davor Pavlović(University of Birmingham), Jonathan P. Law(University Hospitals Birmingham NHS Foundation Trust), Georgios V. Gkoutos(University of Cambridge), André Ziegler(Roche (Switzerland)), Yanish Purmah(University of Birmingham), Paul Brady(University Hospitals Birmingham NHS Foundation Trust)
PLoS Medicine
February 3, 2021
Cited by 18


Related Papers